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The aim of this study was to produce monoclonal antibodies directed to the N-terminal regulatory region of S6K1,
which shows very low homology to S6K2. Methods. Hybridoma technology, ELISA, Western blot, Immunopre-
cipitation. Results. Three hybridoma clones (A1, A2 and A3) producing mAbs specific to ribosomal protein S6
kinase 1 have been generated. Specificity of mAbs has been confirmed by Western blot and immunoprecipitation
technique. Conclusions. The obtained antibodies are suitable for elucidating signal transduction pathways
involving S6K1.
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Introduction. Ribosomal protein S6 kinases (S6Ks)
belong to the AGC family of Ser/Thr kinases, which in- 
cludes PKA, PKCs, PKB/Akt, RSK, SGK and PDK1.
There are two highly homologous isoforms of S6K in
mammalian cells, termed S6K1 and S6K2 [1–4]. Both
isoforms have nuclear (S6K1/I and S6K2/I) and cyto-
plasmic (S6K1/II and S6K2/II) variants originated from
different initiation start codons.  The 23- and 13-amino
acid extensions at the N-termini of S6K1 and S6K2 cor-
respondently possess nuclear localization signals (NLS). 
S6K1 and S6K2 have a similar modular organization,
in which kinase and kinase extension domains are flan-
ked by the regulatory N- and C-terminal regions with
different protein-protein interaction sequences and sig- 
nalling motifs. A high level of homology is shared bet-
ween S6K1 and 2 kinase and kinase extension domains
(83 % and 76 % respectively). However, the N- and C-
terminal regulatory regions of S6K1 and 2 exhibit a low 
level of homology (38 % and 12 % respectively) [5, 6].   
The structure of S6Ks has not been solved so far, but de-
letion/mutational studies suggest that the acidic N-ter-
minal sequences of S6K1/2 interact with positively char-
ged residues in the C-terminal autoinhibitory regions,
thereby keeping their kinase domains in inactive confor-
mations. 
The presence of a PDZ domain-binding motif at the 
C-terminus of S6K1 that is absent in S6K2 implicates
this isoform in regulating cytoskeletal rearrangements
through specific interaction with the PDZ domain of
the F-actin binding protein – neurabin [7, 8]. S6K2 mean-
while, contains a proline-rich region in its C-terminus,
which may facilitate interaction with SH3 domain – or
WW domain-containing molecules [2, 8]. 
Genetic and biochemical studies have linked S6Ks
to diverse cellular processes, including mRNA proces-
sing, translation, glucose homeostasis, cell size and
growth, cellular metabolism and survival. The deregu-
lation of S6Ks function has been closely associated with
a number of diseases, including obesity, diabetes and
cancer. Therefore, S6Ks are considered as good targets
for the development of novel diagnostic and therapeu-
tic approaches.
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S6Ks are activated in response to the growth fac-
tors, hormones and nutrients signalling via the phos-
phatidylinositol 3-kinase (PI3K) and mammalian tar-
get of rapamycin (mTOR) pathways.  In activated state
both isoforms have been shown to associate with and
phosphorylate a diverse range of cellular proteins, in-
cluding the regulators of translation (rpS6, eIF4B, eEF2K
and PDCD4), protein kinases (PDK1, mTOR and PKCs),
small GTPases (Rac and cdc42), ubiquitin ligases (MDM2
and Roc1), pro-survival factors (Bad1) (reviewed in [9]).
At the same time S6K1 and 2 can form distinct multien- 
zyme complexes suggesting different roles of S6K1 and
2 in controlling diverse cellular functions [10–17]. For
example, S6K1, but not S6K2, has been shown to form
a regulatory complex with initiation factor 3 (eIF3), im-
plicating this isoform in controlling the initiation of pro-
tein synthesis [10]. S6K2, but not S6K1, has been found
in complexes with mRNA binding proteins, which be-
long to the family of heterogenous ribonucleoproteins
(hnRNPs) and this  interaction is required for the induc- 
tion of cell proliferation [14].  
Taking this into account, we present in this study the
production and characterization of monoclonal antibo-
dies specific to S6K1 that would be valuable for elucida- 
ting signal transduction pathways involving S6Ks.
Materials and methods. Expression and affinity
purification of GST-S6K2 fusion proteins. A cDNA frag-
ments of rat S6K1, corresponding to N-terminal sequen- 
ces (1–74 aa and 24–74 aa) were amplified by PCR using
specific oligonucleotide primers. All fragments were
cloned into pET42a vector («Novagen», Madison, WI)
in frame with the N-terminal GST and 6His-tag sequen-
ces. Recombinant proteins designated as F1 and F2 cor- 
respondently were expressed in BL21(DE3) Escheri-
chia coli cells. Affinity purification of recombinant pro-
teins from the insoluble fractions of bacterial lysate
was carried out by Ni-NTA-agarose («QIAGEN», Ger- 
many) chromatography at denatured conditions accor-
ding to manufactures recommendations. The purity of
fusion proteins was confirmed by sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis (SDS-PAGE). 
Cell lines. HEK293 (human embryonal kidney),
MCF-7 (human breast adenocarcinoma), NIH/3T3
(mouse embryonic fibroblast), and C6 (rat glial cells)
were propagated in DMEM medium supplemented
with 10 % (v/v) fetal calf serum (FCS) and 2 mM L-
glutamine. Sp 2/0 (mouse myeloma) cells were cultu-
red in RPMI-1640 medium supplemented with 10 %
(v/v) FCS and 2 mM L-glutamine. 
Development of hybridoma. Hybridoma develop-
ment has been performed according to the protocol pub-
lished in [18, 19]. As an antigen for immunization S6K1
N-terminal recombinant peptide F1 has been used.  Po-
sitive hybridoma clones were selected by ELISA for F1 
GST-His fusion peptide and then counter screened
against GST-His alone to eliminate anti-GST clones.
The selected hybridomas were subcloned using limi-
ting dilution method. For further characterization of the 
generated S6K1 specific antibodies the hybridoma cul-
ture supernatant or IgGs purified from ascitic fluid were
used [18].
ELISA assays – F1, F2 recombinant proteins or GST
alone were diluted in PBS (pH 7.4) and incubated for
1 h at 37 °C in 96-well polystyrene plates (0.5  g/well).
To block non-specific binding, the plates were washed
once with PBS containing 0.1 % Tween-20, and incuba-
ted with 200 ml of 2 % bovine serum albumin (BSA) in
PBS (pH 7.4) for 1 h at 37 °C. Subsequently, the plates
were loaded with 100 µl aliquots of hybridoma culture
supernatant and incubated for 1 h at 37 °C. After exten-
sive washing, 100 µl of horseradish peroxidase (HRP)-
conjugated goat anti-mouse IgG antibodies (1:5000 v/v,
«Promega», USA) were added to each well and incuba- 
ted at 37 °C for 1 h. The plates were washed again four
times, then a substrate solution, which contains 0.02 %
H2O2, 0.5 mg/ml 2,2'-Azino-bis(3-ethylbenzothiazoli-
ne-6-sulfonic acid) sodium salt («Sigma-Aldrich», USA)
and 0.1 M citrate-phosphate buffer (pH 5.8) was added
to each well. After 15-min incubation at 37 °C, the light 
absorbance of the each well was determined at 490 nm.
Production and purification of monoclonal antibo-
dies from mouse ascites – BALB/c mice were injected
with 0.5 ml of Pristane and 7–10 days later inoculated
with 5×106 hybridoma cells. The ascitic fluid was collec- 
ted after 10–14 days. The fraction of immunoglobulins
was precipitated from ascitic fluid with 50 % ammo-
nium sulphate and used for affinity purification by Pro- 
tein G-Sepharose CL-4B («GE Healthcare», USA) chro-
matography. The IgG fractions were pulled together
and dialyzed in a phosphate-buffered saline (PBS), pH
7.4. The aliquots of purified antibodies were stored at
–70 °C.
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Western blot analysis. Cell lysates were prepared
using a lysis buffer containing 20 mM Tris-HCl, pH
7.5, 150 mM NaCl, 1 % Triton X-100, 50 mM NaF,
5 mM EDTA, and a mixture of protease inhibitors
(«Roche Molecular Diagnostics», France). Cell lysates
(30 µg) were separated by SDS-PAGE and transferred
onto Immobilon-P membrane («Millipore»,  USA). The
membrane was blocked with 5 % skim milk in TBST
(50 mM Tris-HCl, pH 7.4, 150 mM NaCl and 0.05 %
Tween-20) for 1 h at RT, and then incubated with cultu- 
re supernatants of positive clones for 1 h at RT. After
washing with TBST, the membrane was incubated with 
HRP-conjugated goat anti-mouse IgG in 1:6000 dilu-
tion for 1 h at RT. Finally, the membrane was develo-
ped using ECL kit («GE Healthcare») and then exposed 
to Agfa X-ray film.
Immunoprecipitation. 1µg of mAbs purified from
ascites was incubated with 15 µl of 50 % protein G-Se-
pharose  and 500 µg of cell extract in a total volume of
500 µl lysis buffer and rotated at 4 °C for 3 h. Immune
complexes bound to Protein G-Sepharose beads were
recovered by brief centrifugation and washed three ti-
mes.  Finally, samples were boiled in Laemmli sample
buffer for 5 min, separated by SDS-PAGE and immuno-
blotted with corresponding antibodies. As a negative
control we used Protein G Sepharose beads incubated
with cell lysates and mAbs 2B specific to S6K2 isoform.
Results and discussion. The aim of this study was
to produce monoclonal antibodies specific to the N-ter- 
minal regulatory region of S6K1, which shows very low
homology to S6K2 or other members of the AGC family.
S6K1 mAbs production. A cDNA fragments of S6K1
coding for N-terminal 1–74 aa and 24–74 aa sequences
were cloned into pET42a vector, expressed in E. coli
and recombinant proteins (F1 and F2 correspondently)
were purified as recommended by manufacturer using
Ni-NTA-agarose (Fig. 1, A, B). Peptide F1 covering NLS
located within 1–23 aa sequence of S6K1/I was used as
an antigen for immunization. Following presented sche-
me of immunization the titre of anti-S6K1 antibodies in 
the serum of immunized mice was nearly (10–6) on 45th
day of immunisation. 
Spleen cells from one of the immunized mice were
then fused with SP2/0 myeloma cells. The resulting
hybridoma cells were selected by growing in HAT me-
dium, and tested for the production of anti-S6K1 antibo- 
dies on 10th day after fusion. Screening of ten 96 well
plates with growing hybridomas by ELISA using S6K1 
recombinant peptide F1 as antigens, allowed us to iden- 
tify 12 positive clones. Next, we used the recombinant
GST-His protein as an antigen in second round of
ELISA screening in order to detect the clones produ-
cing antibodies specific to GST-His. Only three from
twelve selected primary clones did not react with GST/
His (data not shown). ELISA screening of these clones
with S6K1 recombinant peptides F1 and F2 demonstra- 
ted positive response to both peptides (data not shown),
indicating that none of the clones was specific to NLS
region (1–23 aa) of S6K1 and the epitops for all three
clones were located within the 24–74 aa sequence of
S6K1 common for both peptides (Fig. 2).
Application of anti-S6K1 mAbs for Western blotting.
To analyse antibodies further we tested all selected clo- 
nes in Western blotting of cell lysates. Taking into ac-
count that for immunization we used the rat S6K1 N-
terminal recombinant fragment we used for the analysis 
rat, mouse and human cell lines.  According to the data
of Western blot, mAbs of all three clones (A1, A2 and
¬F2
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Fig. 1. Expression and afffinity purification of S6K1 recombinant pep-
tides F1 and F2. SDS-PAGE analysis of purified S6K1-GST-His-taged 
fusion peptides F1 (A) and F2 (B): 1, 2 – lysates of bacterial cells before 
and after chromatography; 3, 4 – fractions of eluted purified peptides
F1
24 74 525 aa
1 24 74 525 aa
GST-6His
GST-6His
S6K1/I
S6K1/II
F2
Epitope
Fig. 2.  Schematic representation of S6K1 peptides (F1 and F2) cloned
in pET42a vectors, purified as GST-His-tag fusions from bacteria cells  
and representation of S6K1 epitope localization recognized by mono-
clonal antibodies     
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A3) efficiently recognized the endogenous S6K1/p70
in lysate of rat cell line C6 and to a less extent the S6K1
variants (p85 and p70) in human and mouse cell lines.
Western blot analysis of cell lysates with A2 mAb is
presented in Fig. 3. Data for A1 and A3 mAbs are not
presented. As a positive control we used the anti-S6K1/ 
C-term rabbit polyclonal antibodies that were characte- 
rised and applied in the previous studies [20–22]. The-
se results clearly show that the antibodies produced by
A1, A2 and A3 clones specifically recognize the endo-
genous S6K1. 
Application of anti-S6K1 MAbs for immunopreci-
pitation. To widen a range of applications for the anti-
bodies generated, we tested them in immunoprecipi-
tation of the endogenous S6K1 from cell lysates. For
this purpose we use HEK293 cell lysates. The data pre-
sented in Fig. 4 clearly indicate that all three mAbs pre-
cipitated the endogenous S6K1 (S6K1/p85 and S6K/
p70) as it was further detected in WB by the anti-S6K1/ 
C-term rabbit polyclonal antibodies.
Taken together, this study describes the generation
of three hybridoma clones, which produce the anti-S6K1 
monoclonal antibodies specific to the kinase N-termi-
nal regulatory region. These antibodies are suitable for
various immunoassays, including ELISA, Western blot-
ting and immunprecipitation. The produced antibodies
provide a very useful tool to study the function of S6K1,
its possible isoforms and different macromolecular
complexes they are involved in.
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Ство рен ня  мо нок ло наль них ан титіл, спе цифічних
до кінази 1 ри бо сом но го білка S6
Резюме 
Мета. Отри ма ти мо нок ло нальні ан титіла про ти N-кінце вої ре -
гу ля тор ної ділян ки кінази ри бо сом но го білка S6-S6K1, який має
низ ь кий рівень го мо логії з ізо фор мою S6K2. Ме то ди. Гібри дом на
тех но логія, ІФА, Вес терн-блот, іму ноп ре ципітація. Ре зуль та -
ти. Ство ре но три гібри дом них кло ни (A1, A2 і A3), які про ду ку-
ють мо нок ло нальні ан титіла, спе цифічні до кінази S6K1. Вис нов-
ки. Одер жані мо нок ло нальні ан титіла за свої ми ха рак те рис ти -
кам мож на ви ко рис то ву ва ти для досліджен ня S6K1-за леж них
сиг наль них шляхів. 
Клю чові сло ва: кіназа ри бо сом но го білка S6, МкАТ.
Л. А. Са вин ская, О. H. Кли па, Н. A. Де мук, 
Г. В. Овча рен ко, О. Н. Ма лан чук, И. А. Ти хон ко ва, 
С. С. Паль чев ский, В. В. Фи ло нен ко 
По лу че ние мо нок ло наль ных ан ти тел, спе ци фич ных
к ки на зе 1 ри бо сом но го бел ка S6
Ре зю ме
Цель. По лу чить мо нок ло наль ные ан ти те ла про тив N-кон це во го
ре гу ля тор но го учас тка ки на зы ри бо сом но го бел ка S6 – S6K1, име-
юще го низ кий уро вень го мо ло гии с S6K2 изо фор мой. Ме то ды.
Гиб ри дом ная тех но ло гия, ИФА, Вес терн-блот, им му ноп ре ци пи -
та ция Ре зуль та ты. Соз да ны три гиб ри дом ных кло на (A1, A2 и
A3), про ду ци ру ю щих мо нок ло наль ные ан ти те ла, спе ци фич ные к
ки на зе S6K1. Спе ци фич ность ан ти тел под твер жде на ме то да ми 
Вес терн бло та и им му ноп ре ци пи та ции. Вы во ды. По лу чен ные мо -
нок ло наль ные ан ти те ла по сво им ха рак те рис ти кам мож но ис -
поль зо вать для из уче ния S6K1-за ви си мых сиг наль ных пу тей.
Клю че вые сло ва: ки на за ри бо сом но го бел ка S6, МкАТ.
1            2              3               4           5 
S6K1/p85®
S6K1/p70®
¬IgG/HC
¬IgG/LC
Fig. 4. Monoclonal antibodies against S6K1 (A1, A2, A3) specifically
immunoprecipitate endogenous S6K1 from HEK293 cell lysate. Wes-
tern blot analysis of S6K1 kinase precipitated from HEK 293 cell lysa-
tes by mAbs A1 (3), A2 (4), A3 (5) and detected by anti-S6K1/C-term
polyclonal antibody: 1 – total cell lysate; 2 – immunoprecipitate by
anti-S6K2 mAb B2 [22] as a control 
S6K1/p85®
S6K1/p70®
1         2          3         4          5           6        7         8 
WB:
anti-S6K1/C-term anti-S6K1 (A2)
Fig. 3.  Representative Western blot analysis of MCF7 (1, 5), HEK293
(2, 6), NIH3T3 (3, 7) and C6 (4, 8) cell lysates, with  monoclonal anti-
bodies against S6K1 (clone A2) and rabbit polyclonal anti-S6K1/
C-term
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